<International Circulation>:  You mentioned that you still have a lot of blood samples to process.  What are you going to be looking for?

   《国际循环》：你刚才提到，你仍然有大量的血液样本要研究。您希望得到哪些数据？
 
    Prof. Mahaffey:  We collected a series of blood samples on these patients including sample where we could do very sophisticated platelet studies.  We also collected DNA， RNA， and plasma and serum samples for biomarker assessment.  We are going to be specifically looking at platelet function in the setting of both thienopyridine and Vorapaxar use.   One of the things many people are talking about and that I am very intrigued by is whether there are patients that are genetically predisposed to having an increased risk of bleeding or particularly intracranial hemorrhage.  If we could identify factors that would predispose someone to intracranial hemorrhage when we are deciding on therapies， that would be an intriguing thing to be able to sit with a patient， do blood sampling， and identify the risk of intracranial hemorrhage.  That knowledge could lead a clinician to think twice about treating with blood thinners.  If there was not such a high risk then you would be more likely to treat aggressively with blood thinners because those patients have a risk for heart attacks or stroke.  There is a lot to think about and some really exciting potential for the future.

    Mahaffey教授：我们收集了这些患者一系列的血液样本， 包括我们可以做非常复杂的血小板研究的血液样本。我们还收集了DNA、RNA以及血浆和血清样本以作生物标志物的评估。我们特别要在噻吩并吡啶和Vorapaxar同时服用的情况下，测定血小板功能。很多人都在谈论而我也很感兴趣的事情之一是，是否有患者有出血风险增加的遗传倾向，尤其是颅内出血。如果我们能够识别易颅内出血的患者，当我们决定治疗方案时，能够与病人一起坐下来，做血液样本测定，并确定颅内出血的风险，这将是一个有意义的事情。这些知识可能会让临床医生在血液稀释剂治疗时三思而后行。如果没有这么高的风险，那就可能更积极的应用血液稀释剂，因为这些患者中风的风险更高。有很多需要考虑的，而且有些前景也让人很兴奋。